The standard treatment for physically fit and young patients with advanced chronic lymphocyticleukemia (CLL) and genetic risk factors is the chemoimmunotherapy (CIT) regimen of fludarabine+ cyclophosphamide + rituximab or bendamustine + rituximab, especially in many Europeancountries, where the continuous treatment with Bruton tyrosine kinase inhibitors (BTKi), such asibrutinib, is approved but not reimbursed.¹ In unfit patients, trials have shown greater improvementsin progression-free survival (PFS) with venetoclax + obinutuzumab as a time-limited therapycompared with chlorambucil + obinutuzumab.¹ Other phase 2 trials also demonstrated remarkableimprovements in the undetectable minimal residual disease (MRD) rates with the triple combinationconsisting of adding BTKi to venetoclax + obinutuzumab.¹

Follicular lymphoma (FL) is characterized by periodic relapses, refractoriness, reduced progressionfree survival (PFS), and a low response rate with successive conventional treatment lines. Progression of FL within 24 months from the initial start of therapy (POD24) and its refractory nature result in poor prognosis.¹ Hence, a potent alternative treatment is essential, given the refractory and unyielding nature of FL.

This phase 1/2 study of 90 pretreated patients evaluated the effectiveness of mosunetuzumab, which is a CD20 x CD3 bispecific antibody (Ab) that redirects T cells to destroy malignant B cells.¹ Patients with relapsed/refractory (rr) FL who received at least ≥2 prior lines of therapy (3L + rrFL) were administered with mosunetuzumab monotherapy¹. The selection criteria for the cohort of patients were grade 1-3a FL, the Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1 and at least ≥2 prior lines of therapy.¹ Mosunetuzumab was infused by step-up dosing in cycle 1 (C1) to mitigate the effects of cytokine release syndrome (CRS), facilitating treatment without hospitalization.1 Results after the median follow-up of 18.3 months revealed that mosunetuzumab fixed-term treatment (21 cycles) was durable and increased complete response (CR) rates in FL patients.¹ The study met the primary endpoint with a significantly high CR rate.¹ As per the findings of the study, mosunetuzumab, which can also be administered as an off-the-shelf outpatient therapy, elicited a durable efficacy, a high CR rate and a tolerable safety profile.¹

The Lancet Oncology has recently published the phase 2 study results of a novel EZH2 inhibitor. In patients with advanced or metastatic epithelioid sarcoma (ES) and relapsed or refractory follicular lymphoma (FL) that was previously treated, tazemetostat was shown to be well-tolerated with clinicall

Although chronic lymphocytic leukemia (CLL) patients now have a broader selection of treatment options available, therapeutic efficacies of most treatments still largely depend on the patients’ fitness, cytogenetics and previous treatment responses. Some clinically relevant mutations have now been identified to predict

Primary Sjögren’s Syndrome (pSS) is the second most prevalent systemic autoimmune disease characterized by ocular and oral dryness, musculoskeletal pain, profound fatigue, and an increased risk of lymphoma.¹ Although the symptoms are identifiable, pSS remains incurable due to its